Targets › IL22RA1
2 programs from 2 companies in 14 trials: 7 Phase 3, 6 Phase 2, 1 Phase 1; Immunology, Infectious disease; next expected readout Dec 2026.
Component of the receptor for IL20, IL22 and IL24. Component of IL22 receptor formed by IL22RA1 and IL10RB enabling IL22 signaling via JAK/STAT pathways. (UniProt, Q8N6P7)
Open in Phaseline: the race on IL22RA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Afimkibart Anti-integrin α4β7 monoclonal antibody | ITGA4, ITGB7, IL22RA1 | Phase 3 | Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis … | Dec 2026 |
| Samer Gawrieh | Eflepedocokin Alfa (F-652) IL22 Receptor agonist | IL10RB, IL22RA1 | Phase 2 | Alcohol-associated Hepatitis | Dec 2029 |
Moderately to Severely Active Ulcerative Colitis (4) Moderately to Severely Active Crohns Disease (3) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Crohns Disease (1) Active Ulcerative Colitis (1) Alcohol-associated Hepatitis (1)
antibody (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.